What syndrome can occur in nearly one-third of neonates exposed to SSRIs/SNRIs?

Neonatal adaptation syndrome is characterized by a variety of symptoms that can occur in newborns who have been exposed to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) during pregnancy. This syndrome might manifest as respiratory distress, feeding difficulties, irritability, or abnormal muscle tone shortly after birth.

The brain development of the fetus can be influenced by the exposure to these medications, leading to these adaptive responses as the neonate adjusts to life outside the womb. It is acknowledged that nearly one-third of neonates exposed to such medications may experience this syndrome, highlighting the importance of monitoring these infants post-delivery.

In contrast, while neonatal hypertension, jaundice, and seizures are significant conditions that can occur in neonates, they are not as directly associated with in utero exposure to SSRIs/SNRIs as neonatal adaptation syndrome is.